Plasma Exchange

Phase 2Biologic

Sanofi

Plasma Exchange is one of 156 biologic programs targeting Acute Liver Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

155

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Liver FailureActive, not recruiting

HepatitisActive, not recruiting

Acute-on-Chronic Liver FailureActive, not recruiting

Chronic Liver FailureActive, not recruiting

Autoimmune HepatitisActive, not recruiting

PsychosisActive, not recruiting

COVID-19Active, not recruiting

Thrombotic Thrombocytopenic PurpuraActive, not recruiting

Acute Liver FailurePreclinical

Active, not recruiting

HepatitisPreclinical

Active, not recruiting

Acute-on-Chronic Liver FailurePreclinical

Active, not recruiting

Chronic Liver FailurePreclinical

Active, not recruiting

Autoimmune HepatitisPreclinical

Active, not recruiting

PsychosisPreclinical

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Thrombotic Thrombocytopenic PurpuraPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Plasma Exchange

Sanofi

Phase 2

1 2

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

Selenium

SSWOG Cancer Research Network

Preclinical

1 5

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 6

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 7

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 8

Conventional

PPopulation Health Research Institute

Preclinical

1 9

Moderna COVID-19 Vaccine

Moderna

Preclinical

4 10

COVID-19 Vaccines

UUniversity of British Columbia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Acute Liver Failure

NCT06698991

Q1 2027

N/ANot yet recruiting

Autoimmune Hepatitis

NCT06855667

Q4 2027

N/ANot yet recruiting

Randomized Controlled Trial

NCT06276907

Clinical

Trials by Indication[1]

Acute Liver Failure2 trials

Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06698991·20 enrolled

High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02718079·40 enrolled

Randomized Controlled Trial1 trial

An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06276907·190 enrolled

Psychosis1 trial

Study of Immunotherapy in Autoantibody Positive Psychosis

Completed·UUniversity of Cambridge·N/A·NCT02449746·10 enrolled

COVID-191 trial

Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial

Terminated·FFundacion Clinic per a la Recerca Biomédica·Phase 2·NCT04374539·36 enrolled

Autoimmune Hepatitis1 trial

Efficacy and Safety of Therapeutic Plasma Exchange vs Standard Medical Therapy in Severe Autoimmune Hepatitis.

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06855667·50 enrolled

5 more indications

Hepatitis1 trial

Efficacy of Plasma Exchange Therapy vs Standard Medical Therapy in Severe Alcoholic Hepatitis With High Discriminant Function

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06355726·60 enrolled

Acute-on-Chronic Liver Failure1 trial

Thromboelastography Guides a Multicentre Cluster Controlled Study of Plasma Exchange for Hepatitis B Associated Acute-on-chronic Liver Failure

Unknown status·NNanfang Hospital, Southern Medical University·N/A·NCT04747106·390 enrolled

Chronic Liver Failure1 trial

To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).

Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03162419

Monotherapy1 trial

Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04431375·70 enrolled

Thrombotic Thrombocytopenic Purpura1 trial

A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Completed· Sanofi logo

Sanofi·Phase 2/3·NCT04074187·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Plasma Exchange. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plasma Exchange compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plasma Exchange. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Plasma Exchange

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Trials by Indication[1]

Acute Liver Failure2 trials

Randomized Controlled Trial1 trial

Psychosis1 trial

COVID-191 trial

Autoimmune Hepatitis1 trial

Hepatitis1 trial

Acute-on-Chronic Liver Failure1 trial

Chronic Liver Failure1 trial

Monotherapy1 trial

Thrombotic Thrombocytopenic Purpura1 trial

References

Drug Info

Quick Facts

Related News